AssayIndex
Detection rule · severity medium

AX-R12 — Unresolved shoulder or excessive peak asymmetry

The main peak is too asymmetric, or too close to its nearest impurity, for the reported purity to be reliable.

MEDIUM4,137 records flagged61.54 % of the index
Section 1

The predicate

Published literally. A rule you cannot read is an accusation you cannot check.

asymmetry > 1.50 || nearestImpurityResolution < 1.20
Section 2

Why this rule exists

A purity figure is only as good as the integration that produced it, and an integration is only reliable when the main peak is resolved from its neighbours and roughly symmetric.

The rule applies two criteria. Peak asymmetry above 1.50 — measured at 10 % of peak height, per Ph. Eur. 2.2.46 — means the trailing edge is dragging and the boundary between the main peak and anything eluting after it is a matter of judgement. Resolution below 1.20 to the nearest named impurity means the two peaks share a valley high enough that drop-line and valley-to-valley integration will give materially different answers.

Either condition makes the reported purity a range rather than a number. The index does not discard these records — the material may be perfectly good — but it marks the purity figure as integration-limited and excludes it from the tightest aggregates.

Tirzepatide accounts for a disproportionate share of instances, because the des-Aib2 impurity eluting 0.35 min early frequently appears as an unresolved leading shoulder rather than a separate peak. Retatrutide and the other multi-Aib analogues follow for the same reason. This is the rule that most directly encodes the index's view that method and result are inseparable.

Section 3

Incidence

How often the rule fires, where, and when. A rule that never fires is not calibrated; a rule that fires on half the index is measuring the population rather than screening it.

Records flagged 4,137 n=4137
Share of index 61.54% n=6722
Distinct suppliers 20 n=20
Distinct batches 838 n=4137
SupplierFlaggedRecords in indexRate
Homopeptide40157569.7%
GGPeps33856759.6%
TFC33157357.8%
QSC29449559.4%
WWB28352254.2%
WXT25635372.5%
KP23936465.7%
BCH22431670.9%
QYB20632563.4%
CPC19630963.4%
SSA18329462.2%
SWB18131757.1%
ERP16924768.4%
MKM16827261.8%
JEEP16528358.3%
HJ15624862.9%
FGP13229644.6%
SGN13023056.5%
GL Biochem8212665.1%
QST31030.0%

Flagged records per quarter

2024-Q1: 77 · 2024-Q2: 249 · 2024-Q3: 261 · 2024-Q4: 283 · 2025-Q1: 449 · 2025-Q2: 343 · 2025-Q3: 526 · 2025-Q4: 566 · 2026-Q1: 492 · 2026-Q2: 571 · 2026-Q3: 320

Section 4

Recently flagged

The 30 most recent of 4,137 records flagged by AX-R12. Every flagged record →
ReportCompoundSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041847TB-500JEEPJEEP-2602-V3434Nordanalyt2026-Q399.723.85Supplier-supplied1MARGINAL
AX-2026-042461Kisspeptin-10SWBSWB-2603-D6238Janoshik2026-Q398.354.6596.5Supplier-supplied3FAIL
AX-2026-041727CJC-1295 with DACQSCQSC-2602-E9474Janoshik2026-Q398.886.62105.3Supplier-supplied1MARGINAL
AX-2026-041387BPC-157WWBWWB-2606-H3906Janoshik2026-Q398.954.64Laboratory-retained1MARGINAL
AX-2026-041334SemaglutideWWBWWB-2606-N3192Janoshik2026-Q398.835.04Supplier-supplied1MARGINAL
AX-2026-043029RetatrutideKPKP-2607-H5219Medutest2026-Q395.455.71Supplier-supplied2FAIL
AX-2026-043176Kisspeptin-10GL BiochemGLBI-2608-N8085Medutest2026-Q398.223.3092.5Buyer-sourced2FAIL
AX-2026-043283L-CarnosineCPCCPC-2603-G1651Medutest2026-Q398.1010.1291.8Supplier-supplied1FAIL
AX-2026-042574TB-500ERPERP-2605-S8022VendorInvestigate2026-Q399.542.9196.4Buyer-sourced1MARGINAL
AX-2026-042347SemaglutideHJHJ-2608-C3931VendorInvestigate2026-Q398.803.41100.2Buyer-sourced1MARGINAL
AX-2026-043030RetatrutideKPKP-2607-H5219Kestrel2026-Q395.976.9597.1Supplier-supplied2FAIL
AX-2026-041453RetatrutideQYBQYB-2604-B5660VendorInvestigate2026-Q398.022.55Buyer-sourced1MARGINAL
AX-2026-043106TirzepatideKPKP-2608-D5921PeptideMeter2026-Q398.905.45105.4Supplier-supplied2MARGINAL
AX-2026-041886SemaglutideJEEPJEEP-2607-X3911Nordanalyt2026-Q399.194.0396.4Supplier-supplied2MARGINAL
AX-2026-041742TirzepatideFGPFGP-2603-L9714Janoshik2026-Q399.372.43105.5Supplier-supplied1MARGINAL
AX-2026-041337SemaglutideWWBWWB-2606-N3192Nordanalyt2026-Q398.964.81Supplier-supplied1MARGINAL
AX-2026-042648Melanotan IIGGPepsGGPE-2603-P8735Janoshik2026-Q399.106.97Supplier-supplied4MARGINAL
AX-2026-042535TesamorelinERPERP-2604-W7280Janoshik2026-Q399.193.8992.7Supplier-supplied1MARGINAL
AX-2026-042181IpamorelinHomopeptideHOMO-2608-A9045Janoshik2026-Q399.784.79Supplier-supplied1MARGINAL
AX-2026-043365BPC-157CPCCPC-2602-W2646Medutest2026-Q398.562.80Supplier-supplied1MARGINAL
AX-2026-042180IpamorelinHomopeptideHOMO-2608-A9045Janoshik2026-Q399.394.74105.5Supplier-supplied1MARGINAL
AX-2026-041728CJC-1295 with DACQSCQSC-2602-E9474VendorInvestigate2026-Q398.427.04Buyer-sourced1MARGINAL
AX-2026-043180Kisspeptin-10GL BiochemGLBI-2608-N8085Janoshik2026-Q398.693.37103.8Supplier-supplied2MARGINAL
AX-2026-042577TB-500ERPERP-2605-S8022Janoshik2026-Q399.513.45Supplier-supplied1MARGINAL
AX-2026-041385BPC-157WWBWWB-2606-H3906Medutest2026-Q399.314.31Supplier-supplied1MARGINAL
AX-2026-042184IpamorelinHomopeptideHOMO-2608-A9045Kestrel2026-Q399.274.79103.2Supplier-supplied1MARGINAL
AX-2026-041734CJC-1295 with DACQSCQSC-2602-E9474Medutest2026-Q399.437.17105.5Supplier-supplied2FAIL
AX-2026-041454RetatrutideQYBQYB-2604-B5660Janoshik2026-Q398.842.77Supplier-supplied1MARGINAL
AX-2026-042479Melanotan IISWBSWB-2603-A5707Janoshik2026-Q399.163.6794.5Supplier-supplied1MARGINAL
AX-2026-041538RetatrutideQYBQYB-2602-G6308Medutest2026-Q398.502.85Supplier-supplied2MARGINAL